The potential of next-generation sequencing (NGS) in sarcoma diagnosis and treatment is a topic that has sparked much interest and debate. While NGS holds great promise for personalized medicine, a recent consensus statement highlights some crucial considerations. Sarcomas, a diverse group of cancers, present unique challenges due to their low mutational burden and rarity.
Sarcomas, a diverse group of cancers, present a complex landscape with over 70 distinct subtypes and numerous rare forms. Despite this diversity, sarcomas generally exhibit a low mutational burden, which complicates the application of precision oncology approaches. With the recent availability of NGS, questions arise about its role in sarcoma management.
A multidisciplinary panel of experts, led by César Serrano from the Vall d’Hebron Institute of Oncology, published a consensus review in JAMA Oncology. They critically evaluated the evidence and provided guidance on NGS use in clinical practice. The panel emphasized that while NGS technologies are accessible, their routine use in sarcoma care lacks robust evidence.
Sarcomas can be genomically simple (fusion-driven) or complex (extensive genomic rearrangement), and their low mutational burden often leads to misdiagnosis rates of 10-25% without expert review. This fragmented diagnostic landscape adds to the complexity.
NGS is crucial for identifying "tumor-agnostic targets," genetic characteristics of cancer cells that respond to treatment regardless of origin. It can also reveal heritable genetic predispositions impacting treatment and risk management, similar to other cancers. However, NGS is not yet part of routine clinical care for sarcomas.
The rarity, heterogeneity, and limited molecular understanding of sarcomas have led to a lack of guidelines on NGS use. Serrano and his colleagues aimed to fill this gap and optimize NGS application for high-quality, cost-effective patient care.
Their key findings include the recognition that while NGS can identify genetic alterations, only a small fraction of sarcomas have actionable mutations, and the benefit of matched treatments is limited. Prior to this consensus, no standardized recommendations existed for NGS use in sarcoma care.
The consensus encourages the sequencing of all sarcomas in a research setting using pangenomic tools like whole-genome sequencing with RNA sequencing to drive molecular discovery. The addition of whole transcriptome sequencing is considered a potential game-changer, as RNA expression data has guided nearly half of therapeutic recommendations for rare cancers, including sarcomas.
The consensus group agreed that upfront use of NGS fusion panels for all new sarcoma cases is not recommended, and a definitive diagnosis does not always require NGS. Most sarcoma subtypes display classic histologic features, and traditional pathology, immunohistochemistry, and targeted tests remain sufficient in many cases.
Serrano and his colleagues concluded that approximately two-thirds of sarcomas, especially those with complex karyotypes, are unlikely to harbor specific genetic alterations, suggesting molecular testing often provides no added value for these subtypes. The clinical benefit rate from matched therapy was estimated to be only 0.4% for all patients who underwent NGS.
Accurate sarcoma subtype diagnosis is crucial for effective use of targeted agents. NGS results must be interpreted in the context of expert pathology review and multidisciplinary tumor boards. Testing in nonexpert centers risks misinterpretation and inappropriate treatment recommendations.
For managed care organizations, the consensus strongly advocates for highly selective NGS use. Routine, nonselective NGS for all sarcoma patients is not justified. Testing should be reserved for specific subtypes or clinical scenarios where actionable alterations are likely.
Patients should be referred to sarcoma-expert centers for higher diagnostic accuracy and judicious NGS application. This approach reduces misdiagnosis, avoids unnecessary costs, and improves outcomes. Managed care pathways should ensure NGS results are reviewed by molecular tumor boards, integrating clinical, pathologic, and molecular data before treatment decisions.
And this is the part most people miss: the importance of expert centers and multidisciplinary collaboration in optimizing NGS use for sarcoma patients. It's a complex issue, but one that could significantly impact patient care and outcomes. What are your thoughts on the role of NGS in sarcoma management? Should it be a routine tool, or a carefully selected approach?
